臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"lin z z"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 181-205 / 330 (共14頁)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2020-08-13T06:33:59Z	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment	JIN-YUAN SHIH; Lin Z.-Z.; Yu C.-J.; Cheng A.-L.; Yang P.-C.; Chen K.-Y.; Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.
臺大學術典藏	2020-08-13T06:33:58Z	Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors	Mok T.; Yang C.-H.; Leung L.; Lam K.C.; Lin C.-C.; Hsu H.-H.; Sun C.-T.; JIN-YUAN SHIH; Lin Z.-Z.; Yu C.-J.; Chen G.G.; Hsin M.K.Y.; Lin C.-C.;Hsu H.-H.;Sun C.-T.;Jin-Yuan Shih;Lin Z.-Z.;Yu C.-J.;Chen G.G.;Hsin M.K.Y.;Lam K.C.;Leung L.;Yang C.-H.;Mok T.
臺大學術典藏	2020-08-13T06:33:40Z	The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases	Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; JIN-YUAN SHIH; Lin Z.-Z.; Lan K.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏	2020-08-13T06:33:27Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Yang J.C.-H.; Yu C.-J.; JIN-YUAN SHIH; Lin Z.-Z.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.
臺大學術典藏	2020-08-12T06:35:40Z	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment	Lin Z.-Z.;Hsu C.;Chang Y.-C.;Chong-Jen Yu;Hsu C.-H.;Lin C.-C.;Cheng A.-L.;Yang P.-C.;Yang C.-H.; Lin Z.-Z.; Hsu C.; Chang Y.-C.; CHONG-JEN YU; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.
臺大學術典藏	2020-08-12T06:34:29Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; CHONG-JEN YU; Chen K.-Y.; Shih J.-Y.; Ho C.-C.; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Chong-Jen Yu
臺大學術典藏	2020-08-12T06:34:19Z	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients	Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; CHONG-JEN YU; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Chong-Jen Yu
臺大學術典藏	2020-08-12T06:34:19Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU; Lin Y.-T.; Chen J.-S.; Liao W.-Y.
臺大學術典藏	2020-08-12T02:50:42Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	Lin C.-C.; Yang J.C.H.; Yu C.-J.; Lin Z.-Z.; Chen J.-S.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.
臺大學術典藏	2020-08-12T02:50:37Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Yu C.-J.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Hsu C.-L.; CHAO-CHI HO; Liao W.-Y.; Chen J.-S.; Lin Y.-T.; Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Chao-Chi Ho;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.
臺大學術典藏	2020-08-12T02:50:36Z	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients	Yang J.C.-H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.
臺大學術典藏	2020-08-12T02:42:37Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	Chao Y.; Hsu C.; Lee R.-C.; Lin Z.-Z.; BANG-BIN CHEN; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lin Z.-Z.;Bang-Bin Chen;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Hsu C.-H.;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.
臺大學術典藏	2020-08-11T08:36:55Z	Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment	Cheng A.-L.; Tien Y.-W.; PO-CHIN LIANG; Shao Y.-Y.; Lin Z.-Z.
臺大學術典藏	2020-08-11T08:36:54Z	Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma	Shao Y.; Huang C.; PO-CHIN LIANG; Lin Z.-Z.
臺大學術典藏	2020-08-11T08:36:51Z	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy	Shao Y.-Y.; PO-CHIN LIANG; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z.
臺大學術典藏	2020-07-21T06:46:22Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	Yang J.C.H.; Yu C.-J.; Lin C.-C.; Yao Z.-H.; Lin Z.-Z.; Chen J.-S.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.
臺大學術典藏	2020-07-21T06:46:16Z	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients	Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2020-07-21T06:46:16Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Lin Y.-T.; Chen J.-S.; Liao W.-Y.; CHAO-CHI HO; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2020-07-21T06:09:09Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	Yu C.-J.; Yang J.C.H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.
臺大學術典藏	2020-07-21T06:09:04Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Yu C.-J.; Shih J.-Y.; Yang J.C.-H.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; WEI-YU LIAO; Chen J.-S.; Lin Y.-T.
臺大學術典藏	2020-07-03T08:45:42Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y;Chen B.-B;Da-Liang Ou;Lin Z.-Z;Hsu C.-H;Wang M.-J;Cheng A.-L;Hsu C.; Shao Y.-Y; Chen B.-B; DA-LIANG OU; Lin Z.-Z; Hsu C.-H; Wang M.-J; Cheng A.-L; Hsu C.
臺大學術典藏	2020-05-26T09:27:22Z	High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy	Kao W.-Y.;Lin Z.-Z;Yu C.-T;Kuo H.-P;Chang W.-C;Yu C.-J;Chung C.-Y;Ho M.-L;Wang J.-L;Huang M.-S;Chen C.-H;Chen H.-C;Hsia T.-C;Tsao C.-J;Su W.-C;Lai R.-S;Chu N.-M;Hsieh R.-K;Lin M.-C;Chang G.-C;Chen Y.-M;Chih-Hsin Yang;Perng R.-P; Perng R.-P; CHIH-HSIN YANG; Chen Y.-M; Chang G.-C; Lin M.-C; Hsieh R.-K; Chu N.-M; Lai R.-S; Su W.-C; Tsao C.-J; Hsia T.-C; Chen H.-C; Chen C.-H; Huang M.-S; Wang J.-L; Ho M.-L; Chung C.-Y; Yu C.-J; Chang W.-C; Kuo H.-P; Yu C.-T; Lin Z.-Z; Kao W.-Y.
臺大學術典藏	2020-05-26T09:27:22Z	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy	Yang P.-C.;Pao W;Cheng A.-L;Bean J;Huang C.-L;Shun C.-T;Huang C.-J;Lin Z.-Z;Chen K.-Y;Tsai M.-C;Hu F.-C;Chang Y.-C;Shih J.-Y;Yu C.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Chang Y.-C; Hu F.-C; Tsai M.-C; Chen K.-Y; Lin Z.-Z; Huang C.-J; Shun C.-T; Huang C.-L; Bean J; Cheng A.-L; Pao W; Yang P.-C.
臺大學術典藏	2020-05-26T09:27:19Z	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment	Huang C.-L; CHIH-HSIN YANG; Yeh K.-H; Hu F.-C; Chen K.-Y; Shih J.-Y; Lin Z.-Z; Yu C.-J; Cheng A.-L; Yang P.-C.
臺大學術典藏	2020-05-26T09:27:18Z	Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors	Lin C.-C;Hsu H.-H;Sun C.-T;Shih J.-Y;Lin Z.-Z;Yu C.-J;Chen G.G;Hsin M.K.Y;Lam K.C;Leung L;Chih-Hsin Yang;Mok T.; Lin C.-C; Hsu H.-H; Sun C.-T; Shih J.-Y; Lin Z.-Z; Yu C.-J; Chen G.G; Hsin M.K.Y; Lam K.C; Leung L; CHIH-HSIN YANG; Mok T.

顯示項目 181-205 / 330 (共14頁)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52593137 線上人數 : 656 教育部委託研究計畫計畫執行:國立臺灣大學圖書館